Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) – Pipeline Review, H1 2018’, provides in depth analysis on Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted pipeline therapeutics.

The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Hematological Disorders and Ophthalmology under development targeting Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2)

– The report reviews Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

MolMed SpA

Nippon Kayaku Co Ltd

Pharmaleads SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Overview 7

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Therapeutics Assessment 16

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Companies Involved in Therapeutics Development 21

MolMed SpA 21

Nippon Kayaku Co Ltd 21

Pharmaleads SA 22

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Drug Profiles 23

MT-954 Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

NGR-hTNF Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

PL-265 Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

PL-37 Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Recombinant Protein to Inhibit CD13 for Lymphoma and Solid Tumor Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Inhibit ANPEP for Oncology Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

STR-324 Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ubenimex Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Dormant Products 41

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Discontinued Products 43

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC

3.4.11.2) Product Development Milestones 44

Featured News & Press Releases 44

Apr 19, 2018: Pharmaleads to Present Data on PL37 at BioTrinity 2018 in London 44

Apr 19, 2018: Pharmaleads to Present Data on PL265 at BioTrinity 2018 in London 44

Mar 13, 2018: First subject enrolled in Phase I clinical trial of its non-opioid analgesic STR-324 44

Jan 16, 2018: Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint 44

Jan 04, 2018: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients 45

Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain 45

Jun 01, 2017: MolMed provides update on Zafiride Conditional Marketing Authorization application 46

May 17, 2017: Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema 47

May 15, 2017: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 47

May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting 48

May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore 49

May 04, 2017: Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City 49

Jan 03, 2017: Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 50

Dec 23, 2016: The European Medicines Agency has Validated the Submission of Conditional Marketing Authorisation for NGR-hTNF 51

Dec 06, 2016: MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018 8

Number of Products under Development by Therapy Areas, H1 2018 9

Number of Products under Development by Indication, H1 2018 11

Number of Products under Development by Companies, H1 2018 12

Products under Development by Companies, H1 2018 13

Number of Products under Investigation by Universities/Institutes, H1 2018 14

Products under Investigation by Universities/Institutes, H1 2018 15

Number of Products by Stage and Mechanism of Actions, H1 2018 16

Number of Products by Stage and Route of Administration, H1 2018 18

Number of Products by Stage and Molecule Type, H1 2018 20

Pipeline by MolMed SpA, H1 2018 21

Pipeline by Nippon Kayaku Co Ltd, H1 2018 21

Pipeline by Pharmaleads SA, H1 2018 22

Dormant Products, H1 2018 41

Dormant Products, H1 2018 (Contd..1), H1 2018 42

Discontinued Products, H1 2018 43

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018 8

Number of Products under Development by Therapy Areas, H1 2018 9

Number of Products under Development by Top 10 Indications, H1 2018 10

Number of Products by Stage and Mechanism of Actions, H1 2018 16

Number of Products by Routes of Administration, H1 2018 17

Number of Products by Stage and Routes of Administration, H1 2018 17

Number of Products by Molecule Types, H1 2018 19

Number of Products by Stage and Molecule Types, H1 2018 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports